Q3 2023 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Reduced by Analyst

Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair reduced their Q3 2023 earnings estimates for Repligen in a research report issued on Wednesday, May 3rd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, down from their prior forecast […]

Related Keywords

Canada ,United States ,America ,Craig Hallum ,Stifel Nicolaus ,William Blair ,Keycorp ,Repligen Co ,Repligen Corp ,Nasdaq ,Hanseatic Management Services Inc ,Royal Bank ,Fortis Capital Advisors ,Whittier Trust Co ,Repligen Company Profile ,Deutsche Bank Aktiengesellschaft ,Get Rating ,Bank Aktiengesellschaft ,Management Services ,Capital Advisors ,Asia Pacific Region ,Repligen Daily ,Repligen ,Nasdaq Rgen ,Rgen ,Medical ,75991610 ,Earnings Estimates ,